Acorda Therapeutics Inc ACOR:NASDAQ

Last Price$2.86NASDAQ Previous Close - Last Trade as of 1:00PM ET 11/26/21

Today's Change-0.23(7.44%)
Bid (Size)$2.86 (5)
Ask (Size)$2.99 (1)
Day Low / High$2.80 - 3.10
Volume179.1 K
 

Read more news Recent News

-- Earnings Flash (ACOR) ACORDA THERAPEUTICS Reports Q3 Revenue $31.5M
4:05PM ET 11/09/2021 MT Newswires

...

Acorda Therapeutics to Cut 15% of Staff; Names Chief Operating Officer, Chief Commercial Officer
10:31AM ET 9/09/2021 MT Newswires

Acorda Therapeutics (ACOR) said Thursday it is cutting its workforce by 15% "to reduce costs and more closely align operating expenses with expected...

Top Premarket Decliners
8:07AM ET 8/19/2021 MT Newswires

PharmaCyte Biotech (PMCB) shares slumped 59% after pricing a direct offering of common stock at $5 per share. Virpax Pharmaceuticals (VRPX) shares fell...

-- Earnings Flash (ACOR) ACORDA THERAPEUTICS Posts Q2 Revenue $31.8M
4:08PM ET 8/05/2021 MT Newswires

...

Company Profile

Business DescriptionAcorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY. View company web site for more details
Address420 Saw Mill River Road
Ardsley, New York 10502
Phone+1.914.347.4300
Number of Employees474
Recent SEC Filing11/15/20214
President, Chief Executive Officer & DirectorRonald Cohen
Chief Operating OfficerLauren M. Sabella
Chief Financial OfficerMichael Gesser
Chief Scientific Officer EmeritusAndrew R. Blight

Company Highlights

Price Open$3.06
Previous Close$3.09
52 Week Range$2.80 - 8.66
Market Capitalization$32.0 M
Shares Outstanding11.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$17.89
Beta vs. S&P 500N/A
Revenue$471.4 M
Net Profit Margin-127.77%
Return on Equity-83.30%

Analyst Ratings as of 06/16/2021

Buy
1
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset